Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of subcutaneous rilpivirine long-acting alone or with cabotegravir in healthy adults
NL-OMON51507Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of rilpivirine and cabotegravir, sponsored by Janssen Pharmaceutical. Started Nov 2021; status: active, not recruiting.
02
Drugs
rilpivirinecabotegravir
Beyond the preview
Go deeper on NL-OMON51507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51507.